Products for Research Use Only

ZT55

CAT: 0804-HY-124727-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-124727-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia[1].
CAS Number
2138488-38-5
UNSPSC
12352005
Target
Apoptosis; JAK
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zt55.html
Purity
99.51
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC=C1OC)CC2=CN(O)C3=C2C=CC=C3
Molecular Formula
C17H16N2O3
Molecular Weight
296.32
References & Citations
[1]Hu M, et al. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. J Exp Clin Cancer Res. 2019 Feb 4;38 (1) :49.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2

Alternative Products